Eli Lilly & Co. (NYSE:LLY)

Bull and Bear

Top Analyst Upgrades and Downgrades: ARIAD, FedEx, Genpact, Suncor, Travelers, UPS and More

Stocks were trying to post a recovery on Thursday morning on the heels of three days worth of energy-related selling. Despite a relatively harsh drop, investors have proven over and ...
Read Full Story »
135093244

The Best Stocks of 2014 Part 1: Materials, Consumer, Health, Industrials

Stocks have enjoyed yet another wonderful year in 2014, and the bull market is now more than five and a half years old. With the S&P 500 index up almost ...
Read Full Story »
biotech

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

One sad thing for almost every citizen in the United States is that at one point almost all of us will either have cancer or have a friend or relative ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Eli Lilly, Enphase, Lululemon, SodaStream, Yelp and More

Stocks were lower on Thursday after weak overseas trading. Investors are braced for Friday's key unemployment and payrolls report, and they are still looking for upside from their investment funds. ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Alcatel-Lucent, Apple, FireEye, JDSU Uniphase, Solar Stocks and More

Stocks were firm on Tuesday morning during a shortened week that actually will be full of economic reports. 24/7 Wall St. reviews dozens of analyst research reports each morning of ...
Read Full Story »
470431521

The Highest-Yielding Dividends That Are Safe to Hold

Dividend payments by S&P 500 companies reached an all-time high last year, totaling some $330.8 billion, according to FactSet. As of this March, 418 of the 500 companies in the ...
Read Full Story »
down market

Biotech: The Poster Child for Market Volatility in 2014

When 2014 began, no one promised the stock market would rise in a nice, smooth regal sort of way. Boy, were they right. Stocks have been subject to intense bursts ...
Read Full Story »
139716013

UPS Joins Others Down in the Dumps

United Parcel Service Inc. (NYSE: UPS) reported first-quarter 2014 results before markets opened Thursday, and no surprise, winter weather was its theme of the day. And no surprise either that ...
Read Full Story »
$5

Expired Patents Take a Bite out of Eli Lilly Results

Eli Lilly & Co. (NYSE: LLY) reported first-quarter 2014 results before markets opened Thursday. The pharmaceutical giant posted adjusted diluted earnings per share (EPS) of $0.68 on revenues of $4.68 ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Apple, Intel, Chevron, Exxon, Qualcomm, Citigroup and More

Stocks are hitting new highs ahead of Friday's payrolls report, and investors are looking for upside while wanting to not get caught in the next sell-off. 24/7 Wall St. reviews ...
Read Full Story »
investing

Piper Jaffray Stocks to Buy for S&P 500 Going to 2,100

As the bull market enters its sixth year, the S&P 500 continues to set new highs and intermediate-term measures of market strength have turned positive since February. The old Wall ...
Read Full Story »
Pills

Four Upcoming Catalysts That Could Move Pharmaceutical Stocks

Wall Street firms are famous for their ability to throw conference after conference, year after year. Some are highly respected, and a must-attend for investment firms and portfolio managers. Others ...
Read Full Story »
health care

Merrill Lynch’s Top Health Care Stocks to Buy Now

Very quietly, while momentum stocks zoom up and down, one sector has made an almost stealth like move and is leading the S&P 500 so far this year. With the ...
Read Full Story »
investing

Six New Stocks to Buy in the Piper Jaffray Model Portfolio

Most Wall Street firms run model portfolios for their institutional and retail clients. Like all portfolios, they make weighting changes based on a variety of specifics that can include everything ...
Read Full Story »
biotech

Biotech Buyout Bolsters Novartis Cancer Portfolio

Pharmaceutical giant Novartis A.G. (NYSE: NVS) announced Monday morning that it will acquire startup biotech CoStim Pharmaceuticals. Terms of the deal were not revealed, but it will bolster Novartis's cancer ...
Read Full Story »